A 16-week Randomized, Open-label, Multicenter Study to Assess the Superiority of Secukinumab Over Guselkumab in the Complete Treatment of Ustekinumab Resistant Psoriatic Plaques
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Secukinumab (Primary) ; Guselkumab
- Indications Plaque psoriasis
- Focus Proof of concept; Therapeutic Use
- Acronyms ARROW
- Sponsors Novartis Pharmaceuticals
- 31 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 21 Oct 2019 Planned End Date changed from 29 Nov 2019 to 28 Jan 2020.
- 21 Oct 2019 Planned primary completion date changed from 29 Nov 2019 to 28 Jan 2020.